Dataset Information

Bulk RNA-seq of PC3-derived human prostate cancer xenografts and matched mouse blood following treatment with the bivalent BET bromodomain inhibitor MS645 or the monovalent inhibitor JQ1

ABSTRACT: Male ICR SCID mice (5-6 weeks old) were implanted subcutaneously with 5 x 10^6 PC3 cells. When tumors reached ~200 mm^3, mice were randomized to one of three treatment arms: vehicle, JQ1 (30 mg/kg), or MS645 (20 mg/kg). Compounds were administered intraperitoneally. At study end, mice were sacrificed and matched xenograft tumor and whole-blood specimens were collected and snap-frozen for bulk RNA-seq. Tumor RNA-seq reads were aligned to the human reference genome (GRCh38/hg38) and blood RNA-seq reads to the mouse reference genome (GRCm38/mm10). Differential expression analysis (DESeq2) was used to compare MS645 vs vehicle and JQ1 vs vehicle in each compartment. The study identifies the BRD4-RUVBL1/2 axis as a mediator of intrinsic resistance to monovalent BET bromodomain inhibition in AR-negative prostate cancer and demonstrates that bivalent BET targeting by MS645 reprograms resistant tumors toward a treatment-responsive transcriptional state.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE331378 | GEO | 2026/08/29

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Bromodomain and extra terminal domain (BET) epigenetic ‘reader’ proteins are key regulators of both behavioral and molecular responses to cocaine. In substance use disorder (SUD) models, BET function has primarily been investigated using small molecule inhibitors that prevent both bromodomains of BET proteins from interacting with acetylated histones. Although these inhibitors have been shown to be effective in SUD models, the potential adverse effects of pan-BET inhibition may restrict translational applications. Recently, RVX-208 (also known as apabetalone), a clinically tested, domain-selective BET inhibitor, was found to reduce cocaine conditioned responses and cocaine-induced gene expression in the nucleus accumbens (NAc), while avoiding the learning and memory impairments associated with pan-BET inhibitors. However, the effectiveness of RVX-208 in cocaine self-administration procedures remains unclear. Here, we investigated whether repeated RVX-208 treatment during abstinence altered cocaine seeking-behavior in rats trained to self-administer cocaine. Male and female Sprague Dawley rats underwent 17 days of cocaine or sucrose self-administration, followed by daily treatment with vehicle or RVX-208 (25 mg/kg, i.p.) during a 14-day abstinence period. Next, under extinction conditions, rats in the RVX-208-treated group showed reduced lever pressing compared to vehicle controls, with the effect being more pronounced in males than in females. Sucrose-seeking and open field behavior (distance traveled and time in the center zone) were not significantly affected by RVX-208 treatment. Proteomic analysis of the NAc revealed that RVX-208 modulated several proteins, including those associated with dopamine activity (DRD1 and SLC6A3), transcriptional regulation (NFKB1), glutamate transport (SLC1A2), and ion channel activity (KCNJ10), and many changes were sex-dependent. Collectively, these findings indicate that domain-selective BET inhibition is effective at reducing cocaine-seeking behavior under extinction conditions and point to novel mechanisms that may contribute to its therapeutic effect.

Dataset Information

Bulk RNA-seq of PC3-derived human prostate cancer xenografts and matched mouse blood following treatment with the bivalent BET bromodomain inhibitor MS645 or the monovalent inhibitor JQ1

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets